메뉴 건너뛰기




Volumn 145, Issue 11, 2009, Pages 1313-1316

Disappearance of lentigines in a patient receiving imatinib treatment for familial gastrointestinal stromal tumor syndrome

Author keywords

[No Author keywords available]

Indexed keywords

IMATINIB; STEM CELL FACTOR RECEPTOR;

EID: 72749116409     PISSN: 0003987X     EISSN: 15383652     Source Type: Journal    
DOI: 10.1001/archdermatol.2009.263     Document Type: Article
Times cited : (31)

References (18)
  • 4
    • 72749115279 scopus 로고    scopus 로고
    • Life Raft Group Web site. Accessed August 8, 2008.
    • Familial GIST. Life Raft Group Web site. http://www.liferaftgroup.org/ gist-familial.html. Accessed August 8, 2008.
  • 5
    • 2342582667 scopus 로고    scopus 로고
    • C-kit mutation in generalized lentigines associated with gastrointestinal stromal tumor
    • DOI 10.1159/000077302
    • Shibusawa Y, Tamura A, Mochiki E, Kamisaka K, Kimura H, Ishikawa O. C-kit mutation in generalized lentigines associated with gastrointestinal stromal tumor. Dermatology. 2004;208(3):217-220. (Pubitemid 38594534)
    • (2004) Dermatology , vol.208 , Issue.3 , pp. 217-220
    • Shibusawa, Y.1    Tamura, A.2    Mochiki, E.3    Kamisaka, K.4    Kimura, H.5    Ishikawa, O.6
  • 6
    • 33749459756 scopus 로고    scopus 로고
    • Gastrointestinal stromal tumors: Review on morphology, molecular pathology, prognosis, and differential diagnosis
    • Miettinen M, Lasota J. Gastrointestinal stromal tumors: review on morphology, molecular pathology, prognosis, and differential diagnosis. Arch Pathol Lab Med. 2006;130(10):1466-1478. (Pubitemid 44520713)
    • (2006) Archives of Pathology and Laboratory Medicine , vol.130 , Issue.10 , pp. 1466-1478
    • Miettinen, M.1    Lasota, J.2
  • 7
    • 0344412948 scopus 로고    scopus 로고
    • Imatinib Mesylate Causes Hypopigmentation in the Skin
    • DOI 10.1002/cncr.11812
    • Tsao AS, Kantarjian H, Cortes J, O'Brien S, Talpaz M. Imatinib mesylate causes hypopigmentation in the skin. Cancer. 2003;98(11):2483-2487. (Pubitemid 37466664)
    • (2003) Cancer , vol.98 , Issue.11 , pp. 2483-2487
    • Tsao, A.S.1    Kantarjian, H.2    Cortes, J.3    O'Brien, S.4    Talpaz, M.5
  • 8
    • 0028967971 scopus 로고
    • Expression of the c-kit receptor in hypomelanosis: A comparative study between piebaldism, nevus depigmentosus and vitiligo
    • Dippel E, Haas N, Grabbe J, Schadendorf D, Hamann K, Czarnetzki BM. Expression of the c-kit receptor in hypomelanosis: a comparative study between piebaldism, nevus depigmentosus and vitiligo. Br J Dermatol. 1995;132(2):182-189.
    • (1995) Br J Dermatol , vol.132 , Issue.2 , pp. 182-189
    • Dippel, E.1    Haas, N.2    Grabbe, J.3    Schadendorf, D.4    Hamann, K.5    Czarnetzki, B.M.6
  • 9
    • 24344482523 scopus 로고    scopus 로고
    • Imatinib mesilate (Glivec): A systemic depigmenting agent for extensive vitiligo? [17]
    • DOI 10.1111/j.1365-2133.2005.06813.x
    • Legros L, Cassuto J-P, Ortonne J-P. Imatinib mesilate (Glivec): a systemic depigmenting agent for extensive vitiligo? Br J Dermatol. 2005;153(3):691-692. (Pubitemid 41248249)
    • (2005) British Journal of Dermatology , vol.153 , Issue.3 , pp. 691-692
    • Legros, L.1    Cassuto, J.-P.2    Ortonne, J.-P.3
  • 10
    • 72749088767 scopus 로고    scopus 로고
    • East Hanover, NJ Novartis Pharmaceuticals Corp
    • Gleevec [package insert]. East Hanover, NJ; Novartis Pharmaceuticals Corp; 2006.
    • (2006) Gleevec [Package Insert]
  • 12
    • 1542316943 scopus 로고    scopus 로고
    • Hypopigmentation from imatinib mesylate (Gleevec)
    • Grossman WJ, Wilson DB. Hypopigmentation from imatinib mesylate (Gleevec). J Pediatr Hematol Oncol. 2004;26(3):214.
    • (2004) J Pediatr Hematol Oncol , vol.26 , Issue.3 , pp. 214
    • Grossman, W.J.1    Wilson, D.B.2
  • 13
  • 15
    • 48749104326 scopus 로고    scopus 로고
    • Persistent cutaneous hyperpigmentation after tyrosine kinase inhibition with imatinib for GIST
    • Accessed August 5, 2008
    • Alexandrescu D, Dasanu C, Farzanmehr H, Kauffman L. Persistent cutaneous hyperpigmentation after tyrosine kinase inhibition with imatinib for GIST. Dermatol Online J. 2008;14(7):7. http://dermatology.cdlib.org/147/case-report/ gleevec-hyperpigmentation/doru.html. Accessed August 5, 2008.
    • (2008) Dermatol Online J , vol.14 , Issue.7 , pp. 7
    • Alexandrescu, D.1    Dasanu, C.2    Farzanmehr, H.3    Kauffman, L.4
  • 16
    • 57649166233 scopus 로고    scopus 로고
    • Imatinib-associated hyperpigmentation, a side effect that should be recognized
    • Mcpherson T, Sherman V, Turner R. Imatinib-associated hyperpigmentation, a side effect that should be recognized. J Eur Acad Dermatol Venereol. 2009;23(1):82-83.
    • (2009) J Eur Acad Dermatol Venereol , vol.23 , Issue.1 , pp. 82-83
    • Mcpherson, T.1    Sherman, V.2    Turner, R.3
  • 17
    • 23744512047 scopus 로고    scopus 로고
    • An immunohistochemical evaluation of c-kit (CD-117) expression in malignant melanoma, and results of imatinib mesylate (Gleevec) therapy in three patients
    • DOI 10.1097/00008390-200508000-00008
    • Alexis JB, Martinez AE, Lutzky J. An immunohistochemical evaluation of c-kit (CD-117) expression in malignant melanoma, and results of imatinib mesylate (Gleevec) therapy in three patients. Melanoma Res. 2005;15(4):283-285. (Pubitemid 41127464)
    • (2005) Melanoma Research , vol.15 , Issue.4 , pp. 283-285
    • Alexis, J.B.1    Martinez, A.E.2    Lutzky, J.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.